✦ LIBER ✦

Levodopa: why the controversy?

✍ Scribed by Y Agid; CW Olanow; Y Mizuno

Book ID: 117281416
Publisher: The Lancet
Year: 2002
Tongue: English
Weight: 47 KB
Volume: 360
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(02)09733-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sympatric Speciation: Why the Controvers

Sympatric Speciation: Why the Controversy?

✍ Chris D. Jiggins 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 40 KB

Metabolic syndrome: Why the controversy?

✍ Richard E. Pratley 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 122 KB

Parkinson disease: The controversy of le

Parkinson disease: The controversy of levodopa toxicity in Parkinson disease

✍ Zesiewicz, Theresa A. 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 101 KB

FOOD MARKETING —WHY THE DEARTH OF CONTRO

FOOD MARKETING —WHY THE DEARTH OF CONTROVERSY?

✍ G. R. WINTER 📂 Article 📅 1967 🏛 John Wiley and Sons 🌐 English ⚖ 635 KB

Levodopa in the treatment of Parkinson's

Levodopa in the treatment of Parkinson's disease: Current controversies

📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 27 KB 👁 1 views

## Abstract The original article to which this Erratum refers was published in the September, 2004 issue of __Movement__ Disorders (2004) 19 (9) 997–1005.

Levodopa in the treatment of Parkinson's

Levodopa in the treatment of Parkinson's disease: Current controversies

✍ C. Warren Olanow; Yves Agid; Yoshi Mizuno; Alberto Albanese; U. Bonucelli; Phili 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 1 views

## Abstract Levodopa is the most effective symptomatic agent in the treatment of Parkinson's disease (PD) and the “gold standard” against which new agents must be compared. However, there remain two areas of controversy: (1) whether levodopa is toxic, and (2) whether levodopa directly causes motor